The Blavatnik Fund for Innovation at Yale
Accelerating the translation of early-stage life science research into impactful products.
Since 2017, Yale has supported 90 projects with over $23 million in direct funding through the Blavatnik Fund for Innovation.
The Blavatnik Fund for Innovation at Yale is a $65 million fund, committed to cultivating and transforming Yale's pioneering research into cutting-edge, life-saving solutions within the realm of life sciences. The Fund is made possible by a generous grant from the Blavatnik Family Foundation in support of the commercialization of Yale faculty applied research and technology in the life sciences. The Fund’s integrated approach combines business expertise, intensive guidance, and essential funding to support innovative, Yale investigator-initiated translational research. Completed projects will be better positioned to positively impact human health through startup advancement, partnerships with industry, major industry-sponsored research agreements, and/or external non-dilutive funding.
blavatnik applications
Applications for development and pilot awards are currently closed. We will open applications in Spring 2025 for the Accelerator Awards.
Blavatnik By The Numbers
Last Updated: 03/01/25
90
Funded Projects
35
Biotech Ventures Launched
$23M+
Total Awards
$427M
Raised by Ventures
9
FDA Investigational New Drug (IND) Status
8
Clinical Trials Initiated
2024 Overview
2024 Highlights
- 11 modalities and 15 therapeutic areas
- 122 eligible project applicants
- 42% first-time applicants
- 15 development awards, 8 accelerator awards
- 30% women awardees
2024 Annual Report
2023 Overview
2023 Highlights
- Introduction of Accelerator Awards ($30K) for mid-cycle earlier stage projects
- 92 eligible project applicants
- 64% first-time applicants
- 11 development awards, 6 accelerator awards
- 44% women awardees
2023 Annual Report
